Biotech's 2024 IPO season kicks off with heavy demand for CG Oncology in $380M listing
NEW YORK — Bladder cancer drugmaker CG Oncology will debut on the Nasdaq Thursday morning in what is expected to be the first of at least half a dozen biotech IPOs before the spring.
The late-stage, nearly 14-year-old California company kicked off the class of 2024 with a $380 million upsized listing by selling 20 million shares. CG Oncology’s stock $CGON priced at $19 per share, $1 above the high end of the range it proposed last week. At the IPO price, that would give CG a market value of $1.15 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.